International Journal of Urology · 2013 · 19 citations · 22 references
MedicinePharmacologyUrologyBladder ManagementPain ManagementPain MedicineAnalgesiaBladder DysfunctionBladder Function AssessmentBladder Pain SyndromeInterstitial CystitisPain PhysiologyBladder Wall InflammationCytokine Production By Mast CellsHyaluronic Acid TherapyHyaluronic Acid TreatmentHyaluronidase TherapyHyaluronidase UseUrinary Bladder InflammationZonula Occludens Proteins
OBJECTIVES: To determine whether a potential rat model of bladder pain syndrome could be developed through long-term intermittent intravesical hyaluronidase. METHODS: A total of 64 female Sprague-Dawley rats were divided into a control group, a low-dose hyaluronidase (1 mg/mL) group, a high-dose hyaluronidase (4 mg/mL) group and a hyaluronic acid-treated group. Hyaluronidase was given intravesically three times a week for 1 month. Hyaluronic acid (0.5 mL, 0.8 mg/mL) was introduced intravesically to hyaluronidase-treated rats' bladders. Histological changes, cystometry, nociceptive behaviors, and messenger ribonucleic acid levels of inflammatory factors were evaluated and compared between groups. RESULTS: All hyaluronidase-treated rats showed chronic inflammation and fibrosis, increased and activated mast cells, thinned bladder epithelium with abnormal expressions of uroplakin III and zonula occluden-1, and increased levels of interleukin-6 and intercellular adhesion molecule-1 messenger ribonucleic acid. However, the inflammatory score and levels of interleukin-6 and intercellular adhesion molecule-1 were more significant in the high-dose hyaluronidase group than in the low-dose hyaluronidase group (P < 0.01). Furthermore, hyaluronidase-treated rats showed markedly decreased intercontraction intervals, bladder capacity and increased sensitivity to pain compared with controls (P < 0.01). Hyaluronic acid treatment significantly decreased the inflammatory level, number of mast cells, sensitivity to pain, levels of interleukin-6 and intercellular adhesion molecule-1, and increased intercontraction intervals and bladder capacity (P < 0.01). CONCLUSIONS: Long-term intermittent intravesical hyaluronidase could develop a severe chronic cystitis with diffused fibrosis accompanied by altered histology and bladder function. This chronic cystitis rat model can resemble the clinical and histopathological features of human bladder pain syndrome, and might be a potential valuable model for investigation of this troublesome disease.
22
Bladder Surface Glycosaminoglycans: An Epithelial Permeability Barrier
Lowell Parsons, Don Boychuk, Susan Jones et al. · The Journal of Urology · 1990 · 348 citations
Life Sciences, Pharmacology, Urology +17
Role of inflammation in bladder function and interstitial cystitis
Sonal Grover, Abhishek Srivastava, Richard T. Lee et al. · Therapeutic Advances in Urology · 2011 · 209 citations · Full text
Medicine, Immunology, Urology +11
A Comparison of Multiple Urine Markers for Interstitial Cystitis
Deborah Erickson, Sharon X. Xie, V.P. Bhavanandan et al. · The Journal of Urology · 2002 · 169 citations